MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from royalty
financing arrangement
$75,000K
Net loss
$19,583K
Accounts payable
$4,378K
Proceeds from exercise of
series a warrants, net...
$8,291K
Non-cash interest
expense related to...
$3,133K
Accrued liabilities
$1,836K
Prepaid expenses
-$1,332K
Deferred revenue
$416K
Cash provided by
financing activities
$45,260K
Net cash used in
operating activities
$20,213K
Canceled cashflow
$38,031K
Canceled cashflow
$10,465K
Net (decrease)
increase in cash and cash...
-$23,100K
Canceled cashflow
$65,473K
something is missing
-$25,651K
Proceeds from issuance of
common shares, net of...
-$12,253K
Proceeds from employee
stock purchase plan
-$116K
Payment of property and
equipment financing
$11K
Share-based compensation
expense
-$2,627K
something is missing
-$2,405K
Non-cash interest
expense related to...
-$1,653K
Accounts receivable, net
$1,605K
Inventory
$1,178K
Other receivables
$569K
Research and development
tax credits...
$202K
Amortization of debt costs
-$200K
Depreciation of property and
equipment
-$24K
Operating lease assets and
liabilities
-$2K
Net cash (used in)
provided by investing...
-$88,573K
something is missing
-$44,466K
Acquisition of short-term
investments
$44,081K
Acquisition of property and
equipment
$26K
Back
Back
Cash Flow
Milestone Pharmaceuticals Inc. (MIST)
Milestone Pharmaceuticals Inc. (MIST)
source: myfinsight.com